Advertisement

Ads Placeholder
Loading...

WuXi XDC Cayman Inc

2268.HKHKSE
Healthcare
Medical - Diagnostics & Research
HK$61.15
HK$-0.55(-0.89%)
Hong Kong Market opens in 41h 8m

WuXi XDC Cayman Inc (2268.HK) Stock Competitors & Peer Comparison

See (2268.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Diagnostics & Research Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
2268.HKHK$61.15-0.89%76.9B45.30HK$1.35N/A
2359.HKHK$124.90+0.81%357B16.65HK$7.50+1.46%
3347.HKHK$42.70-2.91%51.8B36.19HK$1.18+0.76%
6127.HKHK$21.22+1.43%29.1B47.16HK$0.45+0.15%
9860.HKHK$4.20+0.00%3B140.00HK$0.03N/A
6667.HKHK$7.38-0.14%1.7B46.13HK$0.16N/A
8037.HKHK$0.69-8.00%673.3M-9.86-HK$0.07N/A
2325.HKHK$0.83+3.75%485.8M83.00HK$0.01N/A
8225.HKHK$0.15+0.00%145.3M7.30HK$0.02N/A
0928.HKHK$0.07+1.37%136.9M-3.70-HK$0.02N/A

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

2268.HK vs 2359.HK Comparison April 2026

2268.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2268.HK stands at 76.9B. In comparison, 2359.HK has a market cap of 357B. Regarding current trading prices, 2268.HK is priced at HK$61.15, while 2359.HK trades at HK$124.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2268.HK currently has a P/E ratio of 45.30, whereas 2359.HK's P/E ratio is 16.65. In terms of profitability, 2268.HK's ROE is +0.16%, compared to 2359.HK's ROE of +0.28%. Regarding short-term risk, 2268.HK is more volatile compared to 2359.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 2268.HK.Check 2359.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions